Latest & greatest articles for alzheimer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Alzheimer’s disease

Alzheimer’s disease is a chronic neurodegenerative disease responsible for the majority of cases of dementia. This progressive disease disrupts memory and thinking due to an accumulation of plaques and tangles in the brain. As the disease progresses, these get progressively worse.

What causes Alzheimer’s diseases is poorly understood, although there is a strong genetic component which could account for the majority (~70%) of the risk. Other risk factors have been identified, such as depression, head injuries and hypertension. Alzheimer’s disease is typically a disease of older people.

Although Alzheimer’s disease cannot currently be cured but it can be managed. With cholinesterase inhibitors being a common intervention as well as memantine (an NMDA receptor antagonist) and psychosocial interventions.

Trip has an extensive collection of research evidence and articles relating to Alzheimer’s disease including clinical guidelines, systematic reviews, synopses, clinical trials and case reports.

Top results for alzheimer

122. Blood Test for Early Diagnosis of Alzheimer's Disease

Blood Test for Early Diagnosis of Alzheimer's Disease Blood Test for Early Diagnosis of Alzheimer’s Disease We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Blood Test for Early Diagnosis of Alzheimer’s Disease Share: Reading time approx. 14 minutes This document was published more than 2 years ago. The nature of the evidence may have changed (...) . Alzheimer’s disease (AD) is the most common cause of dementia [1]. The scientific literature offers a good description of the tissue changes in the brain resulting from Alzheimer’s disease. The prevalence of certain substances, biomarkers, in the cerebrospinal fluid reflects these changes. Alzheimer’s disease can be diagnosed by testing cerebrospinal fluid obtained by lumbar puncture (spinal tap). However, a blood test would be an easier way to diagnose the disease. Four potential biomarkers that can

Swedish Council on Technology Assessement2012

123. Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias

Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias Muayqil T, Camicioli R CRD summary This review concluded (...) that combination therapy with memantine and a cholinesterase inhibitor appeared superior to monotherapy in patients with moderate to severe Alzheimer's Disease. They advised a cautious interpretation due to variation in outcome scales and patient characteristics and said it was unclear whether improvements were clinically significant. The authors’ cautious conclusions and recommendations for practice seem appropriate. Authors' objectives To assess the safety and efficacy of combination therapy with memantine

DARE.2012

124. Quantitative study - other: Social aspect of activity stimuli is related to positive affect in persons with Alzheimer's disease

Quantitative study - other: Social aspect of activity stimuli is related to positive affect in persons with Alzheimer's disease Social aspect of activity stimuli is related to positive affect in persons with Alzheimer's disease | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Social aspect of activity stimuli is related to positive affect in persons with Alzheimer's disease Article Text Care of the older person Quantitative study - other Social aspect of activity stimuli is related to positive affect

Evidence-Based Nursing (Requires free registration)2012

125. Beta amyloid imaging with Positron Emission Tomography (PET) for evaluation of suspected alzheimer's disease or other causes of cognitive decline

Beta amyloid imaging with Positron Emission Tomography (PET) for evaluation of suspected alzheimer's disease or other causes of cognitive decline Beta amyloid imaging with Positron Emission Tomography (PET) for evaluation of suspected alzheimer's disease or other causes of cognitive decline Beta amyloid imaging with Positron Emission Tomography (PET) for evaluation of suspected alzheimer's disease or other causes of cognitive decline BlueCross BlueShield Association Record Status (...) This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation BlueCross BlueShield Association. Beta amyloid imaging with Positron Emission Tomography (PET) for evaluation of suspected alzheimer's disease or other causes of cognitive decline. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 27(5). 2012 Authors' objectives To determine whether evaluating patients with suspected Alzheimer's disease

Health Technology Assessment (HTA) Database.2012

126. Efficacy of psychosocial intervention in patients with mild Alzheimer's disease: the multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY).

Efficacy of psychosocial intervention in patients with mild Alzheimer's disease: the multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY). 22807076 2012 07 18 2012 09 19 2015 02 24 1756-1833 345 2012 Jul 17 BMJ (Clinical research ed.) BMJ Efficacy of psychosocial intervention in patients with mild Alzheimer's disease: the multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY). e4693 10.1136/bmj.e4693 bmj.e4693 To assess the efficacy (...) at 12 months of an early psychosocial counselling and support programme for outpatients with mild Alzheimer's disease and their primary care givers. Multicentre, randomised, controlled, rater blinded trial. Primary care and memory clinics in five Danish districts. 330 outpatients with mild Alzheimer's disease and their 330 primary care givers. Participating dyads (patient and primary care giver) were randomised to control support during follow-up or to control support plus DAISY intervention

BMJ2012 Full Text: Link to full Text with Trip Pro

127. Relapse risk after discontinuation of risperidone in Alzheimer's disease.

Relapse risk after discontinuation of risperidone in Alzheimer's disease. 23075176 2012 10 18 2012 10 23 2016 12 15 1533-4406 367 16 2012 Oct 18 The New England journal of medicine N. Engl. J. Med. Relapse risk after discontinuation of risperidone in Alzheimer's disease. 1497-507 10.1056/NEJMoa1114058 Among patients with Alzheimer's disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation (...) of the medication has not been established. Patients with Alzheimer's disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a response to risperidone therapy were then randomly assigned, in a double-blind fashion, to one of three regimens: continued risperidone therapy for 32 weeks (group 1), risperidone therapy for 16 weeks followed by placebo for 16 weeks (group 2), or placebo for 32 weeks (group 3). The primary outcome was the time to relapse

NEJM2012 Full Text: Link to full Text with Trip Pro

128. Donepezil and memantine for moderate-to-severe Alzheimer's disease.

Donepezil and memantine for moderate-to-severe Alzheimer's disease. 22397651 2012 03 08 2012 03 16 2016 11 22 1533-4406 366 10 2012 Mar 08 The New England journal of medicine N. Engl. J. Med. Donepezil and memantine for moderate-to-severe Alzheimer's disease. 893-903 10.1056/NEJMoa1106668 Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression (...) to moderate-to-severe disease. We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received

NEJM2012

129. Diagnostic testing for Alzheimer's disease

Diagnostic testing for Alzheimer's disease Diagnostic testing for Alzheimer's disease Diagnostic testing for Alzheimer's disease Institute for Clinical and Economic Review (ICER) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institute for Clinical and Economic Review (ICER). Diagnostic testing for Alzheimer's disease. Boston: Institute for Clinical (...) and Economic Review (ICER). 2012 Authors' objectives In April, 2011, for the first time in 27 years, diagnostic criteria for Alzheimer's disease (AD) were revised by clinical and policy experts under the leadership of the National Institutes of Health and the Alzheimer's Association. These new guidelines were the first to include consideration of the findings of multiple forms of biomarker tests and highlighted the major changes that had occurred in how experts think about AD and design studies

Health Technology Assessment (HTA) Database.2012

130. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models

Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models Nagy B, Brennan A, Brandtmuller A, Thomas SK, Sullivan SD, Akehurst R Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of rivastigmine patches or capsules for patients with mild-to-moderate Alzheimer's disease, compared with best supportive care. The authors concluded that rivastigmine

NHS Economic Evaluation Database.2011

131. [Responder analyses for memantine in Alzheimer's disease - Rapid report]

[Responder analyses for memantine in Alzheimer's disease - Rapid report] Responderanalysen zu memantin bei alzheimer demenz [Responder analyses for memantine in Alzheimer's disease - Rapid report] Responderanalysen zu memantin bei alzheimer demenz [Responder analyses for memantine in Alzheimer's disease - Rapid report] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation IQWiG. Responderanalysen zu memantin bei alzheimer demenz. [Responder analyses for memantine in Alzheimer's disease - Rapid report] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 84. 2011 Authors' objectives The research question of the present investigation is as follows:
What is the impact of the responder analyses calculated post hoc by Merz and submitted to the G-BA in the fourth quarter of 2010

Health Technology Assessment (HTA) Database.2011

132. Positron Emission Tomography (PET) for alzheimer's disease

Positron Emission Tomography (PET) for alzheimer's disease Positron Emission Tomography (PET) for alzheimer's disease Positron Emission Tomography (PET) for alzheimer's disease Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Positron Emission Tomography (PET) for alzheimer's disease. Lansdale: HAYES, Inc.. Directory Publication. 2011 Authors' objectives Positron (...) emission tomography (PET) is a three-dimensional (3D) nuclear imaging technique that measures the level of physiologic and biochemical activity or other organic function in an organ or tissue by reflecting the distribution of a radiotracer that has been administered to the patient. PET has been proposed as a method for diagnosing and predicting Alzheimer's disease (AD) and for monitoring and predicting response to treatment for AD. Final publication URL The report may be purchased from: Indexing Status

Health Technology Assessment (HTA) Database.2011

133. A phase II trial of huperzine A in mild to moderate Alzheimer disease

A phase II trial of huperzine A in mild to moderate Alzheimer disease 21502597 2011 04 19 2011 06 20 2016 12 15 1526-632X 76 16 2011 Apr 19 Neurology Neurology A phase II trial of huperzine A in mild to moderate Alzheimer disease. 1389-94 10.1212/WNL.0b013e318216eb7b Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata that may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use for Alzheimer disease (AD). We (...) assessed the safety, tolerability, and efficacy of huperzine A in mild to moderate AD in a multicenter trial in which 210 individuals were randomized to receive placebo (n = 70) or huperzine A (200 μg BID [n = 70] or 400 μg BID [n = 70]), for at least 16 weeks, with 177 subjects completing the treatment phase. The primary analysis assessed the cognitive effects of huperzine A 200 μg BID (change in Alzheimer's Disease Assessment Scale-cognitive subscale [ADAS-Cog] at week 16 at 200 μg BID compared

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

134. Plasma clusterin and the risk of Alzheimer disease.

Plasma clusterin and the risk of Alzheimer disease. CONTEXT: Variants in the clusterin gene are associated with the risk of Alzheimer disease (AD) and clusterin levels have been found to be increased in brain and cerebrospinal fluid of patients with AD. Plasma clusterin was reported to be associated with brain atrophy, baseline disease severity, and rapid clinical progression in patients with AD. OBJECTIVE: To evaluate the potential of plasma clusterin as a biomarker of the presence, severity

JAMA2011

136. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer`s disease from other cortical dementias

Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer`s disease from other cortical dementias 20802215 2011 02 17 2011 04 04 2015 11 19 1468-330X 82 3 2011 Mar Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatr. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. 240-6 10.1136/jnnp.2010.207183 Considering that most semantic dementia (SD) and frontotemporal dementia (FTD) patients (...) show no post-mortem Alzheimer's disease (AD) pathology, cerebrospinal fluid (CSF) biomarkers may be of value for distinguishing these patients from those with AD. Additionally, biomarkers may be useful for identifying patients with atypical phenotypic presentations of AD, such as posterior cortical atrophy (PCA) and primary progressive non-fluent or logopenic aphasia (PNFLA). The authors investigated CSF biomarkers (beta-amyloid 1-42 (Aβ(42)), total tau (T-tau) and phosphorylated tau (P-tau

EvidenceUpdates2011

137. Alzheimer's disease.

Alzheimer's disease. An estimated 24 million people worldwide have dementia, the majority of whom are thought to have Alzheimer's disease. Thus, Alzheimer's disease represents a major public health concern and has been identified as a research priority. Although there are licensed treatments that can alleviate symptoms of Alzheimer's disease, there is a pressing need to improve our understanding of pathogenesis to enable development of disease-modifying treatments. Methods for improving (...) diagnosis are also moving forward, but a better consensus is needed for development of a panel of biological and neuroimaging biomarkers that support clinical diagnosis. There is now strong evidence of potential risk and protective factors for Alzheimer's disease, dementia, and cognitive decline, but further work is needed to understand these better and to establish whether interventions can substantially lower these risks. In this Seminar, we provide an overview of recent evidence regarding

Lancet2011

138. Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer`s disease: a randomized controlled trial

Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer`s disease: a randomized controlled trial 20713437 2010 11 30 2011 04 01 2012 11 15 1477-0873 24 12 2010 Dec Clinical rehabilitation Clin Rehabil Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer's disease: a randomized controlled trial. 1102-11 10.1177/0269215510376004 to determine the efficacy of cognitive stimulation therapy (CST) in the treatment of neuropsychiatric (...) symptoms in patients with Alzheimer's disease. a randomized, controlled, rater-blind clinical trial. the military sanatorium. thirty-two patients with mild to moderate Alzheimer's disease exhibiting marked neuropsychiatric symptoms were included in the study. all 32 patients were randomly assigned to a cognitive stimulation therapy group (n = 16) or a control group (n = 16) for 10 weeks. the efficacy measures included the Mini Mental State Examination and the Neuropsychiatric Inventory. patients

EvidenceUpdates2011

139. Exposure to statins in early old age but not in late old age may be associated with a lower risk of developing Alzheimer's disease

Exposure to statins in early old age but not in late old age may be associated with a lower risk of developing Alzheimer's disease Exposure to statins in early old age but not in late old age may be associated with a lower risk of developing Alzheimer's disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Exposure to statins in early old age but not in late old age may be associated with a lower risk of developing Alzheimer's disease Article Text Prognosis Exposure to statins in early old age but not in late old age may be associated with a lower

Evidence-Based Mental Health2011

140. Cohort study: People with Alzheimer's disease are at increased risk of hip fracture and of mortality after hip fracture

Cohort study: People with Alzheimer's disease are at increased risk of hip fracture and of mortality after hip fracture People with Alzheimer's disease are at increased risk of hip fracture and of mortality after hip fracture | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here People with Alzheimer's disease are at increased risk of hip fracture and of mortality after hip fracture Article Text Care of older person Cohort study People with Alzheimer's disease are at increased risk of hip fracture and of

Evidence-Based Nursing (Requires free registration)2011